Abstract
p53 is a crucial tumor suppressor that is mutated or deleted in a majority of cancers. Exactly how p53 prevents tumor progression has proved elusive for many years; however, this information is crucial to define targets for chemotherapeutic development that can effectively restore p53 function. Bioactive sphingolipids have recently emerged as important regulators of proliferative, apoptotic and senescent cellular processes. In this study, we demonstrate that the enzyme sphingosine kinase 1 (SK1), a critical enzyme in the regulation of the key bioactive sphingolipids ceramide, sphingosine and sphingosine-1-phosphate (S1P), serves as a key downstream target for p53 action. Our results show that SK1 is proteolysed in response to genotoxic stress in a p53-dependent manner. p53 null mice display elevation of SK1 levels and a tumor-promoting dysregulation of bioactive sphingolipids in which the anti-growth sphingolipid ceramide is decreased and the pro-growth sphingolipid S1P is increased. Importantly, deletion of SK1 in p53 null mice completely abrogated thymic lymphomas in these mice and prolonged their life span by ∼30%. Deletion of SK1 also significantly attenuated the formation of other cancers in p53 heterozygote mice. The mechanism of p53 tumor suppression by loss of SK1 is mediated by elevations of sphingosine and ceramide, which in turn were accompanied by increased expression of cell cycle inhibitors and tumor cell senescence. Thus, targeting SK1 may restore sphingolipid homeostasis in p53-dependent tumors and provide insights into novel therapeutic approaches to cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T et al. (2006). High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Biophys Res Commun 342: 1284–1290.
Alesse E, Zazzeroni F, Angelucci A, Giannini G, Di Marcotullio L, Gulino A . (1998). The growth arrest and downregulation of c-myc transcription induced by ceramide are related events dependent on p21 induction, Rb underphosphorylation and E2F sequestering. Cell Death Differ 5: 381–389.
Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G et al. (2004). Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 279: 52487–52492.
Baptiste-Okoh N, Barsotti AM, Prives C . (2008). Caspase 2 is both required for p53-mediated apoptosis and downregulated by p53 in a p21-dependent manner. Cell Cycle 7: 1133–1138.
Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M et al. (2008). Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma 49: 948–954.
Bergelin N, Blom T, Heikkila J, Lof C, Alam C, Balthasar S et al. (2009). Sphingosine kinase as an oncogene: autocrine sphingosine 1-phosphate modulates ML-1 thyroid carcinoma cell migration by a mechanism dependent on protein kinase C-alpha and ERK1/2. Endocrinology 150: 2055–2063.
Bielawski J, Pierce JS, Snider J, Rembiesa B, Szulc ZM, Bielawska A . (2009). Comprehensive quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods Mol Biol 579: 443–467.
Bielawski J, Szulc ZM, Hannun YA, Bielawska A . (2006). Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39: 82–91.
Bringold F, Serrano M . (2000). Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol 35: 317–329.
Chao R, Khan W, Hannun YA . (1992). Retinoblastoma protein dephosphorylation induced by D-erythro-sphingosine. J Biol Chem 267: 23459–23462.
Cuenin S, Tinel A, Janssens S, Tschopp J . (2008). p53-induced protein with a death domain (PIDD) isoforms differentially activate nuclear factor-kappaB and caspase-2 in response to genotoxic stress. Oncogene 27: 387–396.
Cuvillier O, Levade T . (2003). Enzymes of sphingosine metabolism as potential pharmacological targets for therapeutic intervention in cancer. Pharmacol Res 47: 439–445.
Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S et al. (1996). Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381: 800–803.
Dbaibo GS, Pushkareva MY, Rachid RA, Alter N, Smyth MJ, Obeid LM et al. (1998). p53-dependent ceramide response to genotoxic stress. J Clin Invest 102: 329–339.
Debacq-Chainiaux F, Boilan E, Dedessus Le Moutier J, Weemaels G, Toussaint O . (2010). p38(MAPK) in the senescence of human and murine fibroblasts. Adv Exp Med Biol 694: 126–137.
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS et al. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215–221.
El-Assaad W, Kozhaya L, Araysi S, Panjarian S, Bitar FF, Baz E et al. (2003). Ceramide and glutathione define two independently regulated pathways of cell death initiated by p53 in Molt-4 leukaemia cells. Biochem J 376: 725–732.
el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J et al. (1994). WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169–1174.
Hannun YA, Obeid LM . (2008). Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139–150.
Heffernan-Stroud LA, Obeid LM . (2011). p53 and regulation of bioactive sphingolipids. Adv Enzyme Regul 51: 219–228.
Hengst JA, Wang X, Sk UH, Sharma AK, Amin S, Yun JK . (2010). Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorg Med Chem Lett 20: 7498–7502.
Ho LH, Taylor R, Dorstyn L, Cakouros D, Bouillet P, Kumar S . (2009). A tumor suppressor function for caspase-2. Proc Natl Acad Sci USA 106: 5336–5341.
Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1–7.
Jayadev S, Liu B, Bielawska AE, Lee JY, Nazaire F, Pushkareva M et al. (1995). Role for ceramide in cell cycle arrest. J Biol Chem 270: 2047–2052.
Johnson KR, Johnson KY, Crellin HG, Ogretmen B, Boylan AM, Harley RA et al. (2005). Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem 53: 1159–1166.
Jung YS, Qian Y, Chen X . (2010). Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal 22: 1003–1012.
Kang S, Bader AG, Zhao L, Vogt PK . (2005). Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle 4: 578–581.
Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK et al. (2009). Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 69: 6915–6923.
Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J et al. (2009). Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J 23: 405–414.
Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T et al. (2006). Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J 20: 386–388.
Kim SS, Chae HS, Bach JH, Lee MW, Kim KY, Lee WB et al. (2002). P53 mediates ceramide-induced apoptosis in SKN-SH cells. Oncogene 21: 2020–2028.
Kolesnick R, Fuks Z . (2003). Radiation and ceramide-induced apoptosis. Oncogene 22: 5897–5906.
Lee JY, Bielawska AE, Obeid LM . (2000). Regulation of cyclin-dependent kinase 2 activity by ceramide. Exp Cell Res 261: 303–311.
Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R et al. (1998). Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 279: 1552–1555.
Lees JA, Weinberg RA . (1999). Tossing monkey wrenches into the clock: new ways of treating cancer. Proc Natl Acad Sci USA 96: 4221–4223.
Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ et al. (2009). Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 15: 1393–1399.
Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK et al. (2004). Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36: 63–68.
Long JS, Edwards J, Watson C, Tovey S, Mair KM, Schiff R et al. (2010). Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol 30: 3827–3841.
Lopez-Marure R, Ventura JL, Sanchez L, Montano LF, Zentella A . (2000). Ceramide mimics tumour necrosis factor-alpha in the induction of cell cycle arrest in endothelial cells. Induction of the tumour suppressor p53 with decrease in retinoblastoma/protein levels. Eur J Biochem 267: 4325–4333.
Loveridge C, Tonelli F, Leclercq T, Lim KG, Long JS, Berdyshev E et al. (2010). The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem 285: 38841–38852.
Lozano G . (2010). Mouse models of p53 functions. Cold Spring Harb Perspect Biol 2: a001115.
Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M et al. (1995). Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375: 503–506.
Mathews TP, Kennedy AJ, Kharel Y, Kennedy PC, Nicoara O, Sunkara M et al. (2010). Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors. J Med Chem 53: 2766–2778.
Obeid LM, Linardic CM, Karolak LA, Hannun YA . (1993). Programmed cell death induced by ceramide. Science 259: 1769–1771.
Ogretmen B, Hannun YA . (2004). Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4: 604–616.
Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S et al. (1999). Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 147: 545–558.
Olivera A, Spiegel S . (1993). Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature 365: 557–560.
Oskouian B, Sooriyakumaran P, Borowsky AD, Crans A, Dillard-Telm L, Tam YY et al. (2006). Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer. Proc Natl Acad Sci USA 103: 17384–17389.
Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T et al. (2008). A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 112: 1382–1391.
Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissie J, Kohama T et al. (2008). Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther 7: 1836–1845.
Pitson SM . (2011). Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 36: 97–107.
Pitson SM, Xia P, Leclercq TM, Moretti PA, Zebol JR, Lynn HE et al. (2005). Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med 201: 49–54.
Pruett ST, Bushnev A, Hagedorn K, Adiga M, Haynes CA, Sullards MC et al. (2008). Biodiversity of sphingoid bases (“sphingosines”) and related amino alcohols. J Lipid Res 49: 1621–1639.
Pruschy M, Resch H, Shi YQ, Aalame N, Glanzmann C, Bodis S . (1999). Ceramide triggers p53-dependent apoptosis in genetically defined fibrosarcoma tumour cells. Br J Cancer 80: 693–698.
Pyne NJ, Pyne S . (2010). Sphingosine 1-phosphate and cancer. Nat Rev Cancer 10: 489–503.
Ryland LK, Fox TE, Liu X, Loughran TP, Kester M . (2011). Dysregulation of sphingolipid metabolism in cancer. Cancer Biol Ther 11: 138–149.
Sawada M, Kiyono T, Nakashima S, Shinoda J, Naganawa T, Hara S et al. (2004). Molecular mechanisms of TNF-alpha-induced ceramide formation in human glioma cells: P53-mediated oxidant stress-dependent and -independent pathways. Cell Death Differ 11: 997–1008.
Soussi T . (2007). p53 alterations in human cancer: more questions than answers. Oncogene 26: 2145–2156.
Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R et al. (2007). PRAK is essential for ras-induced senescence and tumor suppression. Cell 128: 295–308.
Taha TA, Kitatani K, Bielawski J, Cho W, Hannun YA, Obeid LM . (2005). Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J Biol Chem 280: 17196–17202.
Taha TA, Mullen TD, Obeid LM . (2006). A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochimica et Biophysica Acta (BBA) - Biomembranes 1758: 2027–2036.
Taha TA, Osta W, Kozhaya L, Bielawski J, Johnson KR, Gillanders WE et al. (2004). Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J Biol Chem 279: 20546–20554.
Vadas M, Xia P, McCaughan G, Gamble J . (2008). The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction? Biochim Biophys Acta 1781: 442–447.
Vakifahmetoglu H, Olsson M, Tamm C, Heidari N, Orrenius S, Zhivotovsky B . (2008). DNA damage induces two distinct modes of cell death in ovarian carcinomas. Cell Death Differ 15: 555–566.
Venable ME, Obeid LM . (1999). Phospholipase D in cellular senescence. Biochim Biophys Acta 1439: 291–298.
Vogelstein B LD, Levine AJ . (2000). Surfing the p53 network. Nature 408: 307–310.
Watson C, Long JS, Orange C, Tannahill CL, Mallon E, McGlynn LM et al. (2010). High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol 177: 2205–2215.
Weigert A, Schiffmann S, Sekar D, Ley S, Menrad H, Werno C et al. (2009). Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti-inflammatory phenotype. Int J Cancer 125: 2114–2121.
Weisz L, Oren M, Rotter V . (2007). Transcription regulation by mutant p53. Oncogene 26: 2202–2211.
Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW et al. (2000). An oncogenic role of sphingosine kinase. Curr Biol 10: 1527–1530.
Yoon CH, Kim MJ, Park MT, Byun JY, Choi YH, Yoo HS et al. (2009). Activation of p38 mitogen-activated protein kinase is required for death receptor-independent caspase-8 activation and cell death in response to sphingosine. Mol Cancer Res 7: 361–370.
Zilfou JT, Lowe SW . (2009). Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 1: a001883.
Acknowledgements
This work was supported, in part, by Award Number I01BX000156 from the Biomedical Laboratory Research and Development Service of the VA Office of Research and Development, NIH/NIGMS R01 GM062887, NIH/NCI P01 CA097132—project 3 (to LMO). NIH/NCI P01 CA097132—project 1 (to YAH). American Heart Association Pre-Doctoral Fellowship AHA 081509E (to RWJ), NIH MSTP Training Grant GM08716 (to RWJ, AMDC, LAHS), MUSC Hollings Cancer Center Abney Foundation Scholarship (to RWJ, LAHS), NIH/NIEHS TG T32 ES012878, and NIH/NIEHS National Research Service Award Individual Predoctoral Fellowship F30ES017379 (to LAHS). Liquid chromatography-mass spectrometry analysis of sphingolipids was performed by Lipidomics Shared Resource, MUSC (Methods 2006, 39: 82–91) supported by NCI Grants: IPO1CA097132 and P30 CA 138313 and NIH/NCRR SC COBRE Grant P20 RR017677 as specified in Supplementary Information. Laboratory space in the CRI building of MUSC was supported by the NIH, Grant C06 RR018823 from the Extramural Research Facilities Program of the National Center for Research Resources. Refer to Supplementary Information for individual acknowledgements and the VA disclaimer.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Heffernan-Stroud, L., Helke, K., Jenkins, R. et al. Defining a role for sphingosine kinase 1 in p53-dependent tumors. Oncogene 31, 1166–1175 (2012). https://doi.org/10.1038/onc.2011.302
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.302
Keywords
This article is cited by
-
The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications
Molecular Diagnosis & Therapy (2023)
-
Targeting sphingosine kinase 1 (SK1) enhances oncogene-induced senescence through ceramide synthase 2 (CerS2)-mediated generation of very-long-chain ceramides
Cell Death & Disease (2021)
-
POTEE drives colorectal cancer development via regulating SPHK1/p65 signaling
Cell Death & Disease (2019)
-
The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and Neurodegeneration
Molecular Neurobiology (2019)
-
Sphingolipids and their metabolism in physiology and disease
Nature Reviews Molecular Cell Biology (2018)